Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.
Mamlouk, K
Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. [electronic resource] - Bone marrow transplantation Apr 2005 - 747-54 p. digital
Publication Type: Clinical Trial; Journal Article
0268-3369
10.1038/sj.bmt.1704871 doi
Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Area Under Curve
Busulfan--administration & dosage
Cyclophosphamide--administration & dosage
Female
Graft vs Host Disease--prevention & control
Hematopoietic Stem Cell Transplantation--methods
Humans
Immunosuppressive Agents--administration & dosage
Male
Middle Aged
Prospective Studies
Radiometry
Retrospective Studies
Time Factors
Transplantation Conditioning
Treatment Outcome
Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. [electronic resource] - Bone marrow transplantation Apr 2005 - 747-54 p. digital
Publication Type: Clinical Trial; Journal Article
0268-3369
10.1038/sj.bmt.1704871 doi
Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Area Under Curve
Busulfan--administration & dosage
Cyclophosphamide--administration & dosage
Female
Graft vs Host Disease--prevention & control
Hematopoietic Stem Cell Transplantation--methods
Humans
Immunosuppressive Agents--administration & dosage
Male
Middle Aged
Prospective Studies
Radiometry
Retrospective Studies
Time Factors
Transplantation Conditioning
Treatment Outcome